• Xenetic Biosciences’ partner PeriNess secured Israeli Health Ministry clearance for an investigator-initiated DNase I plus anti-CD19 CAR T study in LBCL.
• Trial targets 12 patients with stable or progressive disease at lymphodepletion, aiming to test whether DNase I improves CAR T expansion and response.
• Study will run at Tel-Aviv Sourasky Medical Center, with initial efficacy readouts planned at 1 and 3 months post-infusion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606040840ACCESSWRNAPR_____1172877) on June 04, 2026, and is solely responsible for the information contained therein.